Partner Headlines - GSK

  1. Brandes Makes a Variety of Reductions in 4th Quarter

    GuruFocus
  2. Stock Futures Up As Oil Behaves; Syngenta Up On ChemChina Deal

    IBD
  3. EXCLUSIVE: Inovio Plans On Producing Zika Vaccine By Q3 2016, ...

    Benzinga
  4. Benzinga's M&A Chatter for Thursday January 28, 2015

    Benzinga
  5. 10 Fund Managers Are Totally Wrong on GlaxoSmithKline

    GuruFocus
  6. Stocks Bring High Dividend Yields to HOTCHKIS & WILEY

    GuruFocus
  7. Dynavax Hepatitis B Vaccine Beats Glaxo's In Trial

    IBD
  8. Dynavax Hepatitis B Vaccine Beats Glaxo's In Trial

    IBD
  9. Jeff Auxier's Holdings Trading Below Peter Lynch Earnings Line

    GuruFocus
  10. Cisco Systems, Microsoft and Intel Bring High Dividend Yields ...

    GuruFocus
  11. The 5 Top-Performing Big-Cap Drug Stocks Of 2015

    IBD
  12. High Dividend Yield Ratios Are Hallmarks of Many Dodge & Cox ...

    GuruFocus
  13. Glaxo's ViiV Acquiring Bristol-Myers' HIV Candidates

    IBD
  14. John Rogers' Holdings Trading Below Peter Lynch Earnings Line

    GuruFocus
  15. 3 Global Investment Ideas From Gurus

    GuruFocus
  16. Relypsa Stock Jumps On Buyout Rumors

    IBD
  17. Skin Disease Drug Costs Jump

    IBD
  18. Valeant, Glaxo, Novartis Skin Drug Prices Have Soared

    IBD
  19. Dodge & Cox Sells Most of Stakes in Chevron, GlaxoSmithKline

    GuruFocus
  20. 3 Investment Ideas of Ariel Investment's Rupal Bhansali

    GuruFocus
  21. Pfizer to Create a New Pharmaceutical Colossus

    GuruFocus
  22. GlaxoSmithKline

    IBD
  23. Gilead Beats Q3 Estimates As HIV Franchise Shines

    IBD
  24. ISIS Pharmaceuticals Earns $5M from GSK for Initiation of Phase ...

    Benzinga
  25. Benzinga's Top Upgrades

    Benzinga
  26. IBM, Schlumberger PTs Lowered; Valeant Downgraded

    IBD
  27. GlaxoSmithKline Has a High (and Dangerous) Dividend Yield

    GuruFocus
  28. Tweedy Browne Global Value Adds to Stake in GlaxoSmithKline

    GuruFocus
  29. Liquidia Technologies And GlaxoSmithKline Advance Existing Collaboration; ...

    Benzinga
  30. 3 Big Drugs Likely To Hit The Market Soon

    IBD
  31. Regulatory Update: GSK and Theravance Announce Intention to File ...

    GuruFocus
  32. Guru Stocks at 52-Week Lows: RDS.A, PTR, UL, BP, GSK

    GuruFocus
  33. Five Prime Therapeutics Announces Initial Data From Ongoing Phase ...

    Benzinga
  34. GSK and Theravance Announce Results From the SUMMIT COPD CV Survival ...

    GuruFocus
  35. UPDATE: GlaxoSmithKline Says Tianjin Explosion Strained Supply ...

    Benzinga
  36. GlasxoSmithKlien Says It Holds Sales Rights To Tenozet In Japan/China ...

    Benzinga
  37. Five Prime Therapeutics Announces Oral Presentation of Initial ...

    Benzinga
  38. Dodge & Cox Acquires Stake in Priceline

    GuruFocus
  39. AptarGroup: The Leader in Dispensing Innovation

    GuruFocus
  40. US Stock Futures Slide Ahead Of Deere, Foot Locker Earnings

    Benzinga
  41. Novartis Acquires Rremaining Rghts to GSK's Ofatumumab to Develop ...

    Benzinga
  42. GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment ...

    GuruFocus
  43. Gilead Q2 Earnings Soar As HCV Shines, HIV Rebounds

    IBD
  44. Week Ahead: FOMC Meeting, GDP and More Earnings

    FoxBusiness
  45. Novartis' Mixed Q2: Sandoz Booms, Alcon Struggles

    IBD
  46. It's Not Too Late To Buy Gilead Sciences

    GuruFocus
  47. Benzinga's Volume Movers

    Benzinga
  48. Can Hepatitis B Be A Blockbuster Bug?

    IBD
  49. BioMarin, Sarepta Muscular Dystrophy Drugs Progress

    IBD
  50. Biotech IPOs Steam Ahead Despite Fears Of Overload

    IBD
  51. 5 NYSE Healthcare Stocks With The Highest ROE

    Benzinga
  52. Jim Cramer Advises His Viewers On GlaxoSmithKline, American International ...

    Benzinga
  53. Billionaire George Soros Ups Two Stakes in First Quarter

    GuruFocus
  54. Weekly 3-Year Low Highlights: GSK, TRP, NOV, CHK

    GuruFocus
  55. Guru Stocks at 52-Week Lows: XOM, WMT, PG, CVX, GSK

    GuruFocus
  56. Axovant IPO Best In 20 Years

    IBD
  57. Axovant Sciences Sets 20-Year Record For Biotech IPOs

    IBD
  58. Isis, Biogen Rare-Disease Drug Aids Infant Survival

    IBD
  59. Will GlaxoSmithKline Cut Its 6% Dividend?

    GuruFocus
  60. Perrigo buys Glaxo OTC drugs

    IBD
  61. Will Perrigo's Glaxo Buy Make It Too Pricey?

    IBD
  62. Big Pharma Companies Are Betting On Regenerative Medicine - Should ...

    GuruFocus
  63. Analyst Says GlaxoSmithKline Acquisition Will Benefit Pfizer

    GuruFocus
  64. 9 International Dividend Dogs With Upside Potential

    GuruFocus
  65. Endo International Acquires Par Pharmaceuticals For $8 Billion

    GuruFocus
  66. Tweedy Browne's Stocks With High Growing Yield

    GuruFocus
  67. Kahn Brothers Ups Investment in 4 Stocks

    GuruFocus
  68. Glaxo more bullish than Q1

    IBD
  69. IPO Stock Watch: Adaptimmune Upsizes But Stock Slips

    IBD
  70. Glaxo Q1 Earnings Miss, But 5-Year Guidance Strong

    IBD
  71. Isis Pharma Up As Bayer Licenses Thrombosis Drug

    IBD
  72. GlaxoSmithKline

    IBD
  73. Novartis EPS beats the Street

    IBD
  74. Taking a Closer Look at GlaxoSmithKline

    GuruFocus
  75. Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative ...

    Benzinga
  76. New Potential HIV Vaccine Drug 'Absolutely 100% Effective' In ...

    Benzinga
  77. Dodge & Cox 2014 Equity Year in Review

    GuruFocus
  78. Why Muscular Dystrophy Is Biotech's Favorite Orphan

    IBD
  79. Making Money With Charles Payne: 02/13/15

    FoxBusiness
  80. Simons-Founded Renaissance Technologies Buys Apple, Closes Facebook, ...

    Benzinga
  81. Stocks Edge Higher Friday; Glaxo, Taiwan Semi Muscle Up

    IBD
  82. Bestinfond's Top 5 New Buys During Q4

    GuruFocus
  83. Mylan Makes Deals In Women's Health, Lung Disease

    IBD
  84. Can GlaxoSmithKline Continue Striving in the Face of World Challenges? ...

    GuruFocus
  85. GlaxoSmithKline Expands Its Portfolio Of Medicines In The US ...

    Benzinga
  86. Benzinga's Weekend M&A Chatter

    Benzinga
  87. Gilead Sciences Still has More Upside

    GuruFocus
  88. Johnson & Johnson Riding High On Ebola Vaccines

    GuruFocus
  89. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  90. Hot Biotech Stocks: Isis, Kite Jump On Big Deals

    IBD
  91. Isis Pharma To Develop GI Drugs With J&J

    IBD
  92. Pfizer, Home of Lipitor and Viagra, Lifts Dividend

    IBD
  93. Ebola Drug Work Continues

    IBD
  94. Viral Investing: Ebola Drug Makers' Varied Strategies

    IBD
  95. BioMarin CEO Sees Big Future For Prosensa Drug

    IBD
  96. Weekly 3-Year Low Highlights: RDS.B, GSK, WPZ, CLR

    GuruFocus
  97. Market Mixed Amid Plan To Spend $300 Million On Ebola Vaccines

    Benzinga
  98. Pfizer Spreading Its Wings Into A New Domain Of Life Sciences

    GuruFocus
  99. Merck Bets $9.5 Billion On Cubist's War On Superbugs

    IBD
  100. GlaxoSmithKline's Move A Testament That Pharma Companies Are ...

    Benzinga
Trading Center